[Aranoza -- a new Russian antineoplastic drug].
Myelosuppression is a toxicity-related limitation for aranoza dosage. The drug proved effective in the treatment of uterine sarcoma, cancer of the head and neck, breast, Hodgkin's disease and lymphosarcoma during stage II of clinical studies. Complete regression was reported in the treatment of melanoma (ca. 12%). Good results of chemoimmunotherapy should be expected in untreated patients as well as intraarterial infusions for local lesions of the extremities. Clinical trials of aranoza used in combined modalities of therapy in various sites continue.
Gorbunova
V A
VA
N.N. Blokhin Center for Oncology Research, Russian Academy of Medical Sciences, Moscow.
Orel
N F
NF
Semina
O V
OV
Egorov
G N
GN
Borodkina
A G
AG
Manziuk
L V
LV
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004359:Drug Therapy, Combination; D006027:Glycosides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007261:Infusions, Intra-Arterial; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy*; D008770:Methylnitrosourea / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors
D000970:Antineoplastic Agents; D006027:Glycosides; D016898:Interferon-alpha; C447099:aranoza; D008770:Methylnitrosourea